Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies.
Wasat MansoorEric J RoelandAafia ChaudhryAstra M LiepaRan WeiHolly KnodererPaolo AbadaAnindya ChatterjeeSamuel J KlempnerPublished in: The oncologist (2021)
This comprehensive analysis examining early weight loss during systemic treatment as a predictor of survival outcomes in patients with advanced gastric and gastroesophageal junction adenocarcinoma (G/GEA) includes a large sample size, reliable on-treatment data reported in well-conducted phase III clinical trials, and global representation of cancer patients with advanced G/GEA. Understanding the impact of on-treatment weight loss is clinically relevant and may represent an opportunity for targeted interventions.
Keyphrases
- phase iii
- weight loss
- clinical trial
- open label
- bariatric surgery
- prognostic factors
- squamous cell carcinoma
- type diabetes
- randomized controlled trial
- roux en y gastric bypass
- machine learning
- double blind
- adipose tissue
- body mass index
- skeletal muscle
- artificial intelligence
- radiation therapy
- lymph node
- young adults
- big data
- study protocol
- squamous cell